Saturday, 15 March 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 15 March 2025
News

AZ laser-focused on 1M target

Posted 13 March 2025 AM

Ensuring chronic kidney disease (CKD) patients have earlier and faster access to treatments is at the top of AstraZeneca’s priority list with the company’s Business Unit Director for Cardiovascular Renal and Metabolism, Cecelia Bagley, spearheading the push for policy reform in Australia.

In recognition of World Kidney Disease Day, Bagley spoke to Pharma in Focus about the urgent need to prioritise CKD as a public health priority.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (37)

Clinical & Medical, R&D (14)

Regulatory, Pharmacovigilance & QA (1)

Other (19)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.